TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Nov 16, 2022 11:46 JST
Source:
Eisai
Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis
TOKYO, Nov 16, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan with the indication of rheumatoid arthritis. nippon medac obtained the manufacturing and marketing approval of Japan's first self-administrable subcutaneous injection formulation of MTX, a first line option for the treatment of rheumatoid arthritis, on September 26, 2022. The product is published to Japan's National Health Insurance Drug Price List, today.
The approval of Metoject in Japan is based on the results of a Phase III clinical trial (MC-MTX.17/RA) conducted in Japan by nippon medac to compare the efficacy and safety of Metoject with that of oral MTX, which consisted of a double-blind phase and an extension phase. Based on the license agreement signed by Eisai and medac GmbH in May 2019, nippon medac will hold the marketing authorization of Metoject, while Eisai will be responsible for product distribution of Metoject in Japan.
"Eisai has established a solid franchise and has extensive sales experience in the rheumatoid arthritis area in Japan. By adding Metoject to Eisai's product lineup, we are now able to contribute to rheumatoid arthritis patients in a wide range of stages from the early stages of treatment," said Terushige Iike, Senior Vice President of Eisai and President of Eisai Japan. "We are committed to making further contributions to address the diversified needs of, and increase the benefits provided to, rheumatoid arthritis patients."
"Metoject is the first drug for which nippon medac obtained its manufacturing and marketing approval in Japan. It is also the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan," said Hirohisa Iriyama, Representative Director and President of nippon medac. "Although the drug is already widely used overseas, Eisai, which has extensive experience in this area, has been entrusted with the marketing of the drug in Japan, where there are an estimated 700,000 to 800,000 rheumatoid arthritis patients1, allowing us to bring the drug to them as a new treatment option. Nippon medac will continue to make further contributions in this area."
For more information, visit www.eisai.com/news/2022/news202278.html.
Media Inquiries:
Eisai Co., Ltd.
Public Relations Department
TEL: +81-(0)3-3817-5120
nippon medac Co., Ltd.
Ueno
TEL: +81-(0)3-6661-6270
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
More Press release >>
Latest Press Release
JCB launches second round of Shopping Mall Shuttle Free Ride Campaign in Guam
Nov 13, 2025 11:00 JST
Establishment of the AI Technology "Large Action Model (LAM)" to Accelerate 1-to-1 Marketing
Nov 12, 2025 19:19 JST
Mitsubishi Power Receives Second H-25 Gas Turbine Order for Chang Chun Petrochemical's Miaoli Factory in Taiwan
Nov 12, 2025 18:43 JST
All-New Delica Mini and eK Space Win RJC Car of the Year Award for 2026
Nov 12, 2025 18:00 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Announces TK-SR Rhodium Material for Use in Probe Pins
Nov 12, 2025 11:00 JST
Hitachi and Tobu Railway launched a co-creation initiative to deliver HMAX on Japanese railways
Nov 11, 2025 17:35 JST
World Premiere of the New Hilux in Asia
Nov 10, 2025 20:29 JST
MHI Signs EPC Contract for Large-Scale Ammonia and Urea Fertilizer Production Complex for the State Concern Turkmenhimiya
Nov 10, 2025 19:51 JST
Mitsubishi Heavy Industries Announces Order Intake, Revenue, and Profit Growth in Strong 1H FY2025, Raises Full-Year Order Intake and Revenue Guidance
Nov 10, 2025 19:17 JST
MHI Reaches a Basic Agreement with J-POWER on the Transfer of its Domestic Onshore Wind Power Business
Nov 10, 2025 18:40 JST
JFCR and NEC Confirm Research Results for Developing Individualized Neoantigen Cancer Vaccines Using Whole-Genome Data
Nov 10, 2025 18:01 JST
NEC Wheelchair Singles Masters 2025 to begin
Nov 10, 2025 17:32 JST
Indicio Secures Investment from NEC X, Accelerating A New Era of User-Controlled Digital Identity
Nov 10, 2025 17:00 JST
The 18th JCB World Conference Held in Incheon, Republic of Korea
Nov 07, 2025 18:00 JST
Olympus Unveils Corporate Strategy
Nov 07, 2025 15:30 JST
TANAKA's New Head Office, TANAKA Building Received The GOOD DESIGN AWARD 2025
Nov 07, 2025 04:00 JST
Honda Unveils Next-generation Technologies at "Honda Automotive Technology Workshop" for Electrified Models to be Launched in Second Half of 2020s
Nov 06, 2025 22:44 JST
Ten organizations have jointly launched a project titled "Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry"
Nov 06, 2025 22:00 JST
Fujitsu to develop new chatbot for Japan Pension Service
Nov 06, 2025 21:24 JST
Stripe and NEC to Provide Face Recognition Payment Service via Stripe Terminal
Nov 06, 2025 17:30 JST
More Latest Release >>